What does PROXYPHARMA LLB do?

PROXYPHARMA LLB is a pharmacy in La Bruyère. Private Limited, started on 24 June 2008, 1 establishment.

What is the address of PROXYPHARMA LLB?

The registered office of PROXYPHARMA LLB is located at Rue de Sclef, Meux 47, 5081 La Bruyère.

Is PROXYPHARMA LLB still active?

Yes. According to the CBE (31 October 2026) PROXYPHARMA LLB is active, legal situation “Normale toestand”, started on 24 June 2008.

Is PROXYPHARMA LLB registered on Peppol?

Yes, PROXYPHARMA LLB is registered on the Peppol network with ID 0208:0898752807.

What is the enterprise number of PROXYPHARMA LLB?

The enterprise number of PROXYPHARMA LLB is BE0898752807.

When was PROXYPHARMA LLB founded?

PROXYPHARMA LLB was founded on 24 June 2008.

Who are the directors of PROXYPHARMA LLB?

According to the 2025 annual accounts, the directors of PROXYPHARMA LLB are: Antoinette Loise, Pierre-Louis Loise, Jean-Luc Loise.

Is PROXYPHARMA LLB a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 June 2008; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did PROXYPHARMA LLB make in 2025?

PROXYPHARMA LLB posted a profit after taxes of € 35,296 in financial year 2025.

What is the revenue of PROXYPHARMA LLB?

As a small company, PROXYPHARMA LLB is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 216,577.

How much does an employee at PROXYPHARMA LLB earn?

The average wage cost per full-time employee at PROXYPHARMA LLB was € 76,400 in 2025: staff costs of € 160,338 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PROXYPHARMA LLB have?

According to the 2025 annual accounts, PROXYPHARMA LLB has 2.1 full-time equivalents (FTE).

PROXYPHARMA LLB (Private Limited) - La Bruyère

Dossier PROXYPHARMA LLB, printed on 31 October 2026 from databakkes.be/en/0898752807/proxypharma-llb. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PROXYPHARMA LLB from La Bruyère, company number BE0898752807, closed financial year 2025 with a result of € 35,296 after tax. For that financial year PROXYPHARMA LLB recorded a gross margin of € 216,577 and equity of € 532,755. Compared with financial year 2024, the result moved from € 34,736 to € 35,296. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Healthy

€ 532,755

▼ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 35,296

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 86,322

▼ 46% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 60,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 160,338

▲ 1% vs 2024

€ 76,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9,060

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 18,538

▼ 34% vs 2024

€ 9,953 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 68,385

▼ 33% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 27,846

▼ 27% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 215,718 Gross margin 2022: € 215,718 First fiscal year in the series	€ 193,245 Gross margin 2023: € 193,245 ▼ 10% vs 2022 (€ 215,718) Unfavourable step	€ 219,510 Gross margin 2024: € 219,510 ▲ 14% vs 2023 (€ 193,245) Favourable step	€ 216,577 Gross margin 2025: € 216,577 ▼ 1% vs 2024 (€ 219,510) Unfavourable step	▼ 1%
Profit after taxes	€ 79,212 Profit after taxes 2022: € 79,212 First fiscal year in the series	€ 71,437 Profit after taxes 2023: € 71,437 ▼ 10% vs 2022 (€ 79,212) Unfavourable step	€ 34,736 Profit after taxes 2024: € 34,736 ▼ 51% vs 2023 (€ 71,437) Unfavourable step	€ 35,296 Profit after taxes 2025: € 35,296 ▲ 2% vs 2024 (€ 34,736) Favourable step	▲ 2%
Equity	€ 551,287 Equity 2022: € 551,287 First fiscal year in the series	€ 572,723 Equity 2023: € 572,723 ▲ 4% vs 2022 (€ 551,287) Favourable step	€ 557,459 Equity 2024: € 557,459 ▼ 3% vs 2023 (€ 572,723) Unfavourable step	€ 532,755 Equity 2025: € 532,755 ▼ 4% vs 2024 (€ 557,459) Unfavourable step	▼ 4%
Total debts	€ 201,542 Total debts 2022: € 201,542 First fiscal year in the series	€ 188,907 Total debts 2023: € 188,907 ▼ 6% vs 2022 (€ 201,542) Favourable step	€ 219,388 Total debts 2024: € 219,388 ▲ 16% vs 2023 (€ 188,907) Unfavourable step	€ 174,799 Total debts 2025: € 174,799 ▼ 20% vs 2024 (€ 219,388) Favourable step	▼ 20%
Cash	€ 140,266 Cash 2022: € 140,266 First fiscal year in the series	€ 39,988 Cash 2023: € 39,988 ▼ 71% vs 2022 (€ 140,266) Unfavourable step	€ 159,032 Cash 2024: € 159,032 ▲ 298% vs 2023 (€ 39,988) Favourable step	€ 86,322 Cash 2025: € 86,322 ▼ 46% vs 2024 (€ 159,032) Unfavourable step	▼ 46%
Retained profit	€ 388,577 Retained profit 2022: € 388,577 First fiscal year in the series	€ 410,013 Retained profit 2023: € 410,013 ▲ 6% vs 2022 (€ 388,577) Favourable step	€ 394,749 Retained profit 2024: € 394,749 ▼ 4% vs 2023 (€ 410,013) Unfavourable step	€ 370,045 Retained profit 2025: € 370,045 ▼ 6% vs 2024 (€ 394,749) Unfavourable step	▼ 6%
Dividend	€ 50,000 Dividend 2022: € 50,000 First fiscal year in the series	€ 50,000 Dividend 2023: € 50,000 Unchanged (€ 50,000) Unchanged	€ 50,000 Dividend 2024: € 50,000 Unchanged (€ 50,000) Unchanged	€ 60,000 Dividend 2025: € 60,000 ▲ 20% vs 2024 (€ 50,000) Unchanged	▲ 20%
Bank debt	€ 46,250 Bank debt 2022: € 46,250 First fiscal year in the series	€ 37,357 Bank debt 2023: € 37,357 ▼ 19% vs 2022 (€ 46,250) Favourable step	€ 28,124 Bank debt 2024: € 28,124 ▼ 25% vs 2023 (€ 37,357) Favourable step	€ 18,538 Bank debt 2025: € 18,538 ▼ 34% vs 2024 (€ 28,124) Favourable step	▼ 34%
Balance sheet total	€ 752,829 Balance sheet total 2022: € 752,829 First fiscal year in the series	€ 761,631 Balance sheet total 2023: € 761,631 ▲ 1% vs 2022 (€ 752,829) Unchanged	€ 776,847 Balance sheet total 2024: € 776,847 ▲ 2% vs 2023 (€ 761,631) Unchanged	€ 707,554 Balance sheet total 2025: € 707,554 ▼ 9% vs 2024 (€ 776,847) Unchanged	▼ 9%
Employees (FTE)	2.2 Employees (FTE) 2022: 2.2 First fiscal year in the series	2.2 Employees (FTE) 2023: 2.2 Unchanged (2.2) Unchanged	2.1 Employees (FTE) 2024: 2.1 ▼ 0.1 vs 2023 (2.2) Unchanged	2.1 Employees (FTE) 2025: 2.1 Unchanged (2.1) Unchanged

Key figures of PROXYPHARMA LLB, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PROXYPHARMA LLB?

What happened at PROXYPHARMA LLB in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 24, 2026 New annual accounts for financial year 2025: profit of € 35,296 (▲ 2% vs 2024). Source: NBB ↗
Jul 22, 2008 New establishment in La Bruyère. KBO
Jun 24, 2008 Start of the company according to the CBE. KBO

In short

From € 79,212 profit in 2022 to € 35,296 profit in 2025.

Paid € 23,902 in corporate taxes since 2022.

Best year ever: 2022, with € 79,212 profit.

On average € 103,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Antoinette Loise Pierre-Louis Loise Jean-Luc Loise

PROXYPHARMA LLB

ISLOIS

Behind PROXYPHARMA LLB are Antoinette Loise, Pierre-Louis Loise and Jean-Luc Loise. Jean-Luc Loise is also behind ISLOIS.

Directors

According to the 2025 annual accounts

Antoinette Loise

Director

Pierre-Louis Loise

Director

Jean-Luc Loise

Director

Also active at: ISLOIS

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Sclef, Meux 47

5081 La Bruyère

2.171.942.737

Rue du Chainia, Meux 79 box A

5081 La Bruyère

Active since 22 July 2008

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

ISLOIS same network

€ 83,670 gross margin · 2025

UNITE TVA DU GROUPE LOISE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0898.752.807

VAT number

BE 0898.752.807

Registered office

Rue de Sclef, Meux 47, 5081 La Bruyère

Names & denominations

PROXYPHARMA LLB

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

24 June 2008

Peppol

Active · Active since 19 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

PROXYPHARMA LLB

Financials

What happened to PROXYPHARMA LLB?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions